Table 2.
Proportion of SHIV immunized monkeys with SIV Gag-peptide specific IFN- γ spot forming cells in PBMC
| Weeks after intravenous SIV challenge |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment | 0 | 1 | 2 | 4 | Cumulative Response | 7 | 12 | 16 | 20 | Cumulative Response |
| SHIV | 0/3a | 1/3 100b | ND | 1/2 40 | 2/8c (25%) | 2/4 91 (±21) | 1/2 211 | 1/3 162 | 3/3 158 (±8) | 9/20d (45%) |
| Depo-SHIV | 1/3 155 | 0/2 | 3/3 132 (±49) | 2/2 272 (±133) | 6/10 (60%) | 3/3 231 (±70) | 2/2 230 (±36) | 3/3 228 (±75) | 3/3 293 (±135) | 17/21 (81%) |
a
The number of animals with positive IFN-γ ELISPOT responses/ total number of animals tested.
b
Corrected (peptide stimulated wells – media only wells) mean number of IFN-γ spot forming cells/106 PBMC in positive samples (±SEM).
c
The total number of samples with positive IFN-γ ELISPOT responses/ total number of PBMC samples collected between week 0 and week 4 PC.
d
The total number of samples with positive IFN-γ ELISPOT responses/ total number of PBMC samples collected between week 0 and week 20 PC.